PathAI

PathAI develops AI tools for pathology with applications in both drug development and clinical diagnostics. For biopharma, PathAI's digital pathology AI accelerates clinical trial enrollment by enabling more precise patient selection based on tissue biomarkers. For clinical diagnostics, the AI provides pathologists with quantitative tissue analysis capabilities beyond what manual review provides. Biopharma companies, CROs, and academic cancer centers use PathAI in clinical trials and diagnostics. In drug development, the ability to identify patients with specific tissue characteristics that predict drug response improves trial efficiency and patient selection. For clinically deployed tools, the AI provides consistent, quantitative measurements of tissue features that contribute to more reproducible diagnoses. PathAI's dual focus on drug development and clinical diagnostics gives it revenue diversity and data advantages. Clinical trial pathology work generates labeled data that improves diagnostic models, while clinical use provides real-world validation for new biomarker discovery. The company has partnerships with major pharma companies and academic institutions.